Amplia has this week reached an important recruitment milestone for its ACCENT trial in pancreatic cancer patients, with enrolment of the first cohort of patients now completed.
The aim of the trial is to test the efficacy of AMP945, when dosed in combination with standard of care gemcitabine/nab-paclitaxel chemotherapy in patients with advanced pancreatic cancer.
Amplia’s CEO and Managing Director, Dr John Lambert said:
“This month, we have opened four additional ACCENT clinical trial sites, taking our total number of sites to seven. We are very pleased to have reached today’s recruitment milestone and we will make further announcements as we reach future milestones and dose escalate AMP945. ”
Read today’s ASX release
